FindTrial
Sign In

TT-4

DRUG2 trials

Sponsors

Portage Biotech, Tarus Therapeutics, Inc.

Conditions

Castrate Resistant Prostate CancerColorectal CancerGastric CancerHepatocellular CarcinomaNon Small Cell Lung CancerPancreatic CancerPleural Mesothelioma MalignantRenal Cell Cancer

Phase 1

TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma
RecruitingNCT04969315
Portage BiotechCastrate Resistant Prostate Cancer, Non Small Cell Lung Cancer, Pleural Mesothelioma Malignant +1
Start: 2023-06-23End: 2029-03-01Target: 35Updated: 2026-09-15
TT-4 As a Single Agent in Subjects with Advanced Selected Solid Tumors
WithdrawnNCT04976660
Tarus Therapeutics, Inc.Colorectal Cancer, Gastric Cancer, Hepatocellular Carcinoma +1
Start: 2022-12-15End: 2023-09-30Updated: 2025-03-18

Related Papers

ADPORT-601: First-in-human study of adenosine 2A (A2A) and adenosine 2B (A2B) receptor antagonists in patients with select advanced solid tumors.
Journal of Clinical Oncology2024-06-013 citations
759 ADPORT-601 (TT-10–101): first-in-human study of adenosine 2A (A2A) and adenosine 2B (A2B) receptor antagonists in participants with selected advanced solid tumors
Regular and Young Investigator Award Abstracts2023-10-311 citations
Abstract P042: Phase I/II first-in-human study of TT-10 (A2AB inhibitor) as a single agent in subjects with advanced selected solid tumors
Molecular Cancer Therapeutics2021-12-01